[#item_full_content]INGELHEIM, Germany & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– #CancerResearch–Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. Uncontrolled cell growth is a common feature in most tumor types and is a driving force in the formation of tumors. Genetic alterations like mutati